Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.80-0.60 (-9.37%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.40
Open5.81
Bid5.72 x 1100
Ask5.90 x 800
Day's Range5.70 - 6.28
52 Week Range3.17 - 9.70
Volume260,397
Avg. Volume65,546
Market Cap132.159M
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.00
Earnings DateMar 06, 2023 - Mar 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
  • PR Newswire

    DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

    DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 3

  • Zacks

    Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?

    Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • PR Newswire

    DURECT Announces 1-for-10 Reverse Stock Split

    DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m. Eastern Time on December 5, 2022. Beginning with the opening of trading on December 6, 2022, the Company's common stock will trade on a split-adjusted basis.

Advertisement
Advertisement